Since the foundation of the European Society for Dermatological Research, pathogenesis of
psoriasis has been studied by many research groups, focusing on various compartments of …

Introduction Randomised controlled trials (RCTs) have compared biological and targeted
systemic disease-modifying antirheumatic drugs (DMARDS) against placebo in psoriatic …

Emerging biologics, such as monoclonal antibodies (mAbs), are the most promising
treatment for psoriasis, while their effective delivery to the local inflammatory area of the skin …

Recent knowledge on the key role of interleukin (IL) 23/17 axis in psoriasis pathogenesis,
led to development of new biologic drugs. Risankizumab is a humanized immunoglobulin …

Background and objectives A new, updated AEDV Psoriasis Group (GPs) consensus
document on the treatment of moderate to severe psoriasis was needed owing to the …

Introduction The long-term benefit–risk profiles of licensed and investigational treatments for
moderate-to-severe plaque psoriasis have not been fully characterized. Methods …

Abstract Background Psoriatic arthritis (PsA) is a chronic inflammatory arthritis characterised
by musculoskeletal and extra‐articular manifestations, most notably psoriasis. While the …

Background Real-world data on the use of interleukin-17 (IL-17) inhibitors for the treatment
of psoriasis are limited. Objective To evaluate and compare the efficacy, safety, and drug …

Psoriasis is a non-communicable, heterogeneous, autoimmune, inflammatory skin disease
characterised by reddish, scaly plaques that grow over time. Psoriasis affects people in all …

Background Nail psoriasis (NP) is common and of high importance in patients with psoriasis.
Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for …